SCHEMBL6034602

SCHEMBL6034602

Cn1cc(CC(=O)O)c(OCCCc2cn(-c3ccc(C(F)(F)F)cn3)nc2C2CCCCC2)n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.38
GCGR P47871 1/20 0.35
GIPR P48546 1/20 0.35
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
PPARD Q03181 2/20 0.34
PPARA Q07869 2/20 0.34
SMO Q99835 1/20 0.34
GCG P01275 3/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 1/20 0.33
S100A4 P26447 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ABL1 P00519 1/20 0.33
LMNA P02545 1/20 0.33
PTGES O14684 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035942 0.87 PTGDR2 (0.36) PTGDR2GCGRGIPRPPARDPPARA
SCHEMBL6035938 0.86 PPARG (0.39) PTGDR2GCGRGIPRPPARDPPARA
SCHEMBL6035533 0.85 PTGDR2 (0.37) PTGDR2GCGRGIPRPPARDPPARA
SCHEMBL6035764 0.85 HCRTR1 (0.36) PTGDR2GCGRHCRTR1HCRTR2PPARD
SCHEMBL6035903 0.84 SMN1; SMN2 (0.41) GCGRHCRTR1HCRTR2PPARDPPARA
SCHEMBL6036155 0.84 HCRTR1 (0.36) PTGDR2GCGRHCRTR1HCRTR2GCG
SCHEMBL6035190 0.84 GCGR (0.35) PTGDR2GCGRGIPRHCRTR1HCRTR2
SCHEMBL6035906 0.83 HCRTR1 (0.40) PTGDR2GCGRGIPRHCRTR1HCRTR2
SCHEMBL1632906 0.83 GCGR (0.34) GCGRHCRTR1HCRTR2PPARDGCG
SCHEMBL6035724 0.83 PPARD (0.40) PTGDR2HCRTR1HCRTR2PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PTGDR2 4688/4885GCGR 93/4885GIPR 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.